Biogen (BIIB) Trades Lower on Eli Lilly (LLY) Solanezumab Failure

November 23, 2016 6:52 AM EST

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Biogen (NASDAQ: BIIB) is trading down 1% in pre-open trade following news Eli Lilly and Company (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk

Related Entities

Pre Market Movers

Add Your Comment